PMID- 32635219
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 3
TI  - Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction 
      in Spain, According to DAPA-HF Study Criteria.
LID - 10.3390/jcm9072089 [doi]
LID - 2089
AB  - Heart failure (HF) is one of the main causes of morbidity, mortality, and high 
      healthcare costs. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) 
      inhibitor, reduced cardiovascular mortality and hospitalization for HF compared 
      to placebo in patients with chronic HF, and reduced ejection fraction (EF) in the 
      Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) 
      study. Our aim was to estimate the number of patients with DAPA-HF 
      characteristics in Spain. Our literature review identified epidemiological 
      studies whose objective was to quantify the prevalence of HF and its 
      comorbidities in Spain. We estimated the prevalence of HF with reduced EF, of New 
      York Heart Association (NYHA) functional class II-IV, and with a glomerular 
      filtration rate (GFR) >/= 30 mL/min/1.73 m(2). In this population, we analysed the 
      prevalence of diabetes using data from the REDINSCOR (Spanish Network for Heart 
      Failure) registry. Our estimations indicate there are 594,684 patients >/=45 years 
      old with HF in Spain (2.6% of this population age group), of which 52.4%, 84.0%, 
      and 93.9% have reduced EF, are NYHA II-IV, and have a GFR >/= 30 mL/min/1.73 m(2), 
      respectively. By our calculations, approximately 245,789 Spanish patients would 
      meet the DAPA-HF patient profile, and therefore could benefit from the protective 
      cardiovascular effects of dapagliflozin.
FAU - Camps-Vilaro, Anna
AU  - Camps-Vilaro A
AUID- ORCID: 0000-0001-9644-8421
AD  - REGICOR Study Group, IMIM (Hospital del Mar Medical Research Institute), 08003 
      Barcelona, Spain.
AD  - CIBER of Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III 
      (ISCIII), 28029 Madrid, Spain.
FAU - Delgado-Jimenez, Juan F
AU  - Delgado-Jimenez JF
AUID- ORCID: 0000-0002-5401-8324
AD  - CIBER of Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III 
      (ISCIII), 28029 Madrid, Spain.
AD  - Department of Cardiology, Hospital Universitario 12 de Octubre, 28041 Madrid, 
      Spain.
AD  - Faculty of Medicine, Complutense University of Madrid (UCM), 28040 Madrid, Spain.
FAU - Farre, Nuria
AU  - Farre N
AUID- ORCID: 0000-0003-3110-6572
AD  - Department of Cardiology, Hospital del Mar, 08003 Barcelona, Spain.
AD  - Heart Diseases Biomedical Research Group (GREC), IMIM (Hospital del Mar Medical 
      Research Institute), 08003 Barcelona, Spain.
AD  - Faculty of Medicine, Universitat Autonoma de Barcelona (UAB), 08193 Barcelona, 
      Spain.
FAU - Tizon-Marcos, Helena
AU  - Tizon-Marcos H
AD  - Department of Cardiology, Hospital del Mar, 08003 Barcelona, Spain.
AD  - Heart Diseases Biomedical Research Group (GREC), IMIM (Hospital del Mar Medical 
      Research Institute), 08003 Barcelona, Spain.
FAU - Alvarez-Garcia, Jesus
AU  - Alvarez-Garcia J
AUID- ORCID: 0000-0002-2015-6446
AD  - CIBER of Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III 
      (ISCIII), 28029 Madrid, Spain.
AD  - Faculty of Medicine, Universitat Autonoma de Barcelona (UAB), 08193 Barcelona, 
      Spain.
AD  - Department of Cardiology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, 
      Spain.
FAU - Cinca, Juan
AU  - Cinca J
AD  - CIBER of Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III 
      (ISCIII), 28029 Madrid, Spain.
AD  - Faculty of Medicine, Universitat Autonoma de Barcelona (UAB), 08193 Barcelona, 
      Spain.
AD  - Department of Cardiology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, 
      Spain.
FAU - Degano, Irene R
AU  - Degano IR
AD  - REGICOR Study Group, IMIM (Hospital del Mar Medical Research Institute), 08003 
      Barcelona, Spain.
AD  - CIBER of Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III 
      (ISCIII), 28029 Madrid, Spain.
AD  - Faculty of Medicine, University of Vic-Central University of Catalonia 
      (UVic-UCC), 08500 Vic, Spain.
FAU - Marrugat, Jaume
AU  - Marrugat J
AUID- ORCID: 0000-0003-3320-554X
AD  - REGICOR Study Group, IMIM (Hospital del Mar Medical Research Institute), 08003 
      Barcelona, Spain.
AD  - CIBER of Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III 
      (ISCIII), 28029 Madrid, Spain.
LA  - eng
GR  - CIBERCV CB16/11/00229/Spain's Ministry of Science and Innovation (Madrid, Spain), 
      co-financed with European Union European Regional Development Funds -ERDF-/
GR  - 2017SGR222/Health Department of the Generalitat de Catalunya (Barcelona, Spain) 
      through the Agencia de Gestio d'Ajuts Universitaris de Recerca de Catalunya 
      (AGAUR) (Barcelona, Spain)/
GR  - SLT006/17/00029 to IRD/Strategic Plan for research and health innovation (PERIS) 
      (Barcelona, Spain)/
GR  - to J.A.-G./Private Foundation Daniel Bravo Andreu (Barcelona, Spain)/
GR  - -/CIBER of Cardiovascular Diseases (CIBERCV) is an initiative of the Instituto de 
      Salud Carlos III (Madrid, Spain)/
PT  - Journal Article
DEP - 20200703
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7408645
OTO - NOTNLM
OT  - cardiovascular disease
OT  - cardiovascular therapy
OT  - dapagliflozin
OT  - epidemiology
OT  - heart failure
OT  - prevalence
OT  - reduced ejection fraction
OT  - sodium-glucose cotransporter-2 inhibitor
COIS- J.F.D.-J. reports consultancy fees from AstraZeneca; N.F. reports grants and 
      consultancy fees from Novartis, Bayer, Rovi, and AstraZeneca; J.A.-G. reports 
      consultancy fees from AstraZeneca, Boehringer Ingelheim, and Lilly; J.M. reports 
      grants and consultancy fees from AstraZeneca, Sanofi, Shire, Gilead, 
      Daichii-Sankyo, Genincode, and Ferrer. The other authors declare no conflict of 
      interest. The funders had no role in the design of the study; in the collection, 
      analyses, and interpretation of data; in the writing of the manuscript; and in 
      the decision to publish the results.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
PMCR- 2020/07/03
CRDT- 2020/07/09 06:00
PHST- 2020/06/09 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
PHST- 2020/07/03 00:00 [pmc-release]
AID - jcm9072089 [pii]
AID - jcm-09-02089 [pii]
AID - 10.3390/jcm9072089 [doi]
PST - epublish
SO  - J Clin Med. 2020 Jul 3;9(7):2089. doi: 10.3390/jcm9072089.